- Activity pressure is positive on the latest completed week.
BSX
NYSE
Week ended 07 Aug 2026
Weekly Investor Report
Boston Scientific Corp · Healthcare · Medical Devices
Latest close
49.31 USD
5.5%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is -19.4% below the Trend Line and sits at 10.6% of its 52-week range. The latest completed week returned 5.5%, after a 10.1% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive. Options positioning is mixed with 35/100 conviction, while the latest news-sentiment score is 61/100. Near-term considerations: volume confirmation is below normal.
Setup score
28
out of 100
Latest Close
49.31 USD
7 Aug 2026
1W Return
5.5%
latest completed week
4W Return
10.1%
short-term follow-through
12W Return
-6.4%
quarterly tape
Trend Breadth
11.5%
6 of 52 weeks active
Volume Ratio
0.9x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Next-week expectancy is negative at 40.91% based on similar historical setup states.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
5.5%
Latest completed week; four-week move 10.1%.
Indicator stack
6/61
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 40.91%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
Options pressure
Mixed
35/100 conviction; expected move 4.4%.
News sentiment
61/100
22 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -19.4% below the Trend Line and sits at 10.6% of its 52-week range. The latest completed week returned 5.5%, after a 10.1% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0212-week average 0.01
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure1/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.02Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 10.1% over four weeks, -6.4% over 12 weeks, and -52.2% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year6
Trend breadth11.5%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.10Latest activity-pressure read.
Pressure change113.2%Four-week change in activity pressure.
Leadership-44.01Latest relative-leadership reading.
RS change14.4%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 30 Jun 2026
Field coverage 94%
Model confidence 94%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength24/100Blend of value, momentum, and quality. Underlying universe rank 77; rank 1 is best.
Value26/100Relative valuation strength. Underlying universe rank 75; rank 1 is best.
Quality91/100Profitability and accounting quality. Underlying universe rank 10; rank 1 is best.
Momentum9/100Medium-term price momentum. Underlying universe rank 92; rank 1 is best.
Growth85/100Revenue and earnings growth. Underlying universe rank 16; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework55/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 19.5x Price divided by trailing earnings.
- Price / sales
- 3.4x Market value relative to trailing revenue.
- EV / EBITDA
- 15.2x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 6.5% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 71.2% Gross profit retained from each unit of revenue.
- Operating margin
- 20.1% Operating profit retained from revenue.
- Free-cash-flow margin
- 25.9% Free cash flow generated from revenue.
- Return on invested capital
- 10.8% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 13.5% Latest one-year revenue growth.
- EPS growth
- 46.6% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- 3.3% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 7/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 2.2x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningMixed
BSX shows mixed options pressure with a 35/100 conviction score, put-call volume ratio of 1.47, expected move of 4.4%, and Sharemaestro trend signal inactive.
Conviction35/100
Expected move4.4%
Put/call volume1.47
Insider activity17 / 3
17 acquisitions and 3 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment61/100
Weighted news tone is positive across 22 relevant articles.
11 positive · 10 neutral · 1 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move4.4%Nearest-chain priced movement where available.
52-week drawdown-55.0%Distance below the 52-week high.
13-week volatility6.0%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher9 of 2617 weeks finished lower.
Best week+9.7%Week of 22 May.
Worst week-16.4%Week of 29 May.
Latest week+5.5%Week of 7 Aug.
Shape of recent returns
Strong gains3
Modest gains6
Flat weeks0
Modest losses12
Sharp losses5
Recent vol6.0%13-week weekly-return volatility.
Base vol5.1%52-week weekly-return volatility.
Up/down split22/30Count of positive and negative weeks in the 52-week window.
Average skew2.8% / -4.3%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank21 / 100
Group average2.6%
Trend breadth54.0%
Trend54.0%active weekly trend signals
MD77.0%positive activity pressure
RS44.0%positive relative leadership
Four-week leaders
IndustryUS Medical Devices
4-week rank34 / 100
Group average3.4%
Trend breadth38.0%
Trend38.0%active weekly trend signals
MD67.0%positive activity pressure
RS35.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape22/100
Trend, activity pressure, participation, and risk combine to a 22/100 tape read.
Indicator analysis10/100Latest 12-week confirmation: trend 0/12, activity pressure 1/12, relative leadership 0/12.
Activity pressure 0.02; No reversal markers Next-Week ExpectancyNegative 40.91%Next-week expectancy is negative with a 40.91% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors38/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 62 SVQF55/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 456.5 of 1018 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options51/100BSX shows mixed options pressure with a 35/100 conviction score, put-call volume ratio of 1.47, expected move of 4.4%, and Sharemaestro trend signal inactive.
Mixed · Options-market disagreement · Expected move 4.4% Sentiment61/100Weighted news tone is positive across 22 relevant articles.
Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet Insiders17 / 317 acquisitions and 3 disposals in the latest 180-day insider tape.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 49.31 USD | 5.5% | 61.17 USD | 78.87 USD | 0.10 | -44.01 | 91.3M | Off |
| 31 Jul 2026 | 46.73 USD | 5.6% | 62.78 USD | 78.88 USD | -0.26 | -45.98 | 142.8M | Off |
| 24 Jul 2026 | 44.25 USD | 0.5% | 64.38 USD | 78.90 USD | -0.57 | -49.21 | 86.6M | Off |
| 17 Jul 2026 | 44.03 USD | -1.7% | 66.10 USD | 78.95 USD | -0.65 | -50.63 | 82.1M | Off |
| 10 Jul 2026 | 44.77 USD | -0.8% | 67.82 USD | 79.01 USD | -0.79 | -51.42 | 68.1M | Off |
| 3 Jul 2026 | 45.14 USD | 2.1% | 69.42 USD | 79.06 USD | -0.86 | -51.18 | 116.8M | Off |
| 26 Jun 2026 | 44.23 USD | -2.3% | 71.16 USD | 79.11 USD | -0.95 | -51.93 | 106.3M | Off |
| 19 Jun 2026 | 45.29 USD | -3.5% | 73.07 USD | 79.17 USD | -0.95 | -52.77 | 79.1M | Off |
| 12 Jun 2026 | 46.91 USD | -3.4% | 74.79 USD | 79.23 USD | -0.90 | -51.44 | 91.9M | Off |
| 5 Jun 2026 | 48.55 USD | 0.5% | 76.65 USD | 79.27 USD | -1.03 | -50.23 | 118.6M | Off |
| 29 May 2026 | 48.31 USD | -16.4% | 78.37 USD | 79.29 USD | -1.20 | -52.45 | 150.2M | Off |
| 22 May 2026 | 57.78 USD | 9.7% | 80.12 USD | 79.31 USD | -1.38 | -43.26 | 78.6M | Off |
| 15 May 2026 | 52.68 USD | -2.3% | 81.56 USD | 79.27 USD | -1.45 | -48.57 | 85.0M | Off |
| 8 May 2026 | 53.93 USD | -4.5% | 83.11 USD | 79.28 USD | -1.49 | -48.03 | 91.6M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.